Vita Therapeutics is at the forefront of cellular medicine, utilizing advanced technologies such as induced pluripotent stem cells (iPSCs) and CRISPR-based genome editing. iPSCs are generated from somatic cells through the expression of specific transcription factors, allowing them to differentiate into any human cell type. This capability enables Vita to engineer targeted cell therapies aimed at replacing defective cells in patients, addressing the root causes of diseases rather than merely alleviating symptoms. The company focuses on two primary methodologies: the autologous approach, which involves patient-specific therapies, and the allogeneic approach, which aims to develop universal therapies that can be applied to a broader patient population.

Vita's innovative strategies include correcting genetic defects in patient-derived stem cells and reintroducing healthy cells back into the patient to restore normal function. By leveraging the regenerative potential of iPSCs and employing CRISPR technology for precise genome editing, Vita aims to treat conditions such as muscular dystrophies effectively. The company is also committed to creating cost-effective universal cell types, which would enhance the scalability of their therapies and improve access to these novel treatments for patients with unmet medical needs. Through these efforts, Vita Therapeutics aspires to redefine the landscape of cell therapy and significantly improve patient outcomes.

United States

Vita Therapeutics - We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform.  Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.

Cancer

Genetic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Vita Therapeutics

Limb-Girdle Muscular Dystrophy

VTA-100

Biologics

Cell Therapies

Facioscapulohumeral muscular dystrophy

VTA-120

Solid tumor/s

VTA-300

Muscular dystrophy

VTA-200

Maryland

Gene Editing/CRISPR

Gene Therapy

Regenerative Medicine

Stem Cells

Therapeutic

Vita Therapeutics

Company Details